Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.3 to v3.5.0 at the top of the page. This is a minor version update that does not alter study details.
    Difference
    0.1%
    Check dated 2026-03-25T20:52:09.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3. The visible study content and layout remain unchanged.
    Difference
    0.1%
    Check dated 2026-03-11T17:28:18.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    A reference to a 2012 NEJM article on PD-L1 was removed from the page’s references.
    Difference
    0.1%
    Check dated 2026-03-04T14:27:33.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    Deleted the bibliographic reference 'Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.' from the page. This removal does not alter the study design, endpoints, or other critical trial details.
    Difference
    0.1%
    Check dated 2026-02-25T10:30:26.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added and the older funding-status notice (v3.4.1) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T04:55:27.000Z thumbnail image
  8. Check
    60 days ago
    Change Detected
    Summary
    Added a site-wide notice about funding status and operations and updated the page version from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T04:36:15.000Z thumbnail image

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.